Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 

Published byAlexandra Maxwell Modified over 5 years ago

Similar presentations

Presentation on theme: "Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation "— Presentation transcript:

1 Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation  Veronika Bachanova, John Rogosheske, Ryan Shanley, Linda J. Burns, Sara M. Smith, Daniel J. Weisdorf, Claudio G. Brunstein  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages (March 2016) DOI: /j.bbmt Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 (A) Cumulative incidence of relapse by weight groups and (B) Kaplan-Meier estimate of OS by weight groups. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation "

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 
Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.
Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.
FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma 

FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma 
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma  Navneet S. Majhail, Daniel J. Weisdorf,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 

Similar presentations

Ads by Google